Spotlight On... Side-effects analysis gives Merck's new hep C med Zepatier an edge over older drugs; Lilly's Portrazza nabs NSCLC approval in Europe; Allergan's Avycaz gets FDA priority review for new use; and more...

Merck & Co.'s ($MRK) hep C combo Zepatier has just hit the market, but the drug is already winning kudos for its side-effects profile. In a new analysis of clinical trial data, Zepatier turned up proportionally fewer serious side effects than Gilead Sciences' ($GILD) hep C combo treatment Harvoni and its veteran hep C med Sovaldi. Overall, Advera Health Analytics' report deemed Zepatier safer than Sovaldi and on par with Harvoni. More from FiercePharmaMarketing

> European regulators blessed Eli Lilly's ($LLY) oncology med Portrazza as a treatment for patients with advanced non-small cell lung cancer. Report

> Allergan ($AGN) is a step closer to a new use for its infection-fighter Avycaz, as the FDA granted priority review to a new indication in complicated intra-abdominal infections. Release

> Astellas and Medivation ($MDVN) said the FDA is now reviewing an application to add new trial data to the labeling for their prostate cancer treatment Medivation. Release

> South Africa's Adcock Ingram says it's in advanced talks for a potential sale of its Indian sales and marketing unit. Report

And Finally... European drugmakers say a "Brexit" from the EU would threaten scientific research and jeopardize the current system of drug regulation in the region. Report

Suggested Articles

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.

Mylan is taking coronavirus support to Sesame Street, backing Sesame Workshop's ongoing work to help children and parents cope with the pandemic.

Opdivo's wins in front-line gastric and esophageal cancers comes a year after Merck's Keytruda flopped in the same setting.